.Pharmacolibrary.Drugs.ATC.D.D10AD01

Information

Tretinoin (all-trans retinoic acid) is a derivative of vitamin A. It is primarily used in topical form for the treatment of acne vulgaris and has been approved for this indication by regulatory agencies such as the FDA. Systemically, it is also used to induce remission in acute promyelocytic leukemia (APL).

Pharmacokinetics

Pharmacokinetics reported for healthy adult volunteers (both sexes) after a single oral dose.

References

1. Napolitano, M, et al., & Patruno, C (2022). Alitretinoin for the treatment of severe chronic eczema of the hands. Expert opinion on pharmacotherapy 23(2) 159–167. DOI:10.1080/14656566.2021.1998457 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34789049

2. Regazzi, MB, et al., & Liberati, AM (1998). Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off. Clinical drug investigation 16(1) 25–33. DOI:10.2165/00044011-199816010-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18370515

3. Rigas, JR, et al., & Warrell, RP (1993). Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. Journal of the National Cancer Institute 85(23) 1921–1926. DOI:10.1093/jnci/85.23.1921 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8230282

Revisions

• 06/2025 initial generated model